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Abstract : The expression of transcription factor forkhead box protein 3 （FOXP3）, 
a master control gene for regulatory T cells, has been reported to inuence patient 
survival.  However, there have been few reports of the relationship between 
FOXP3 positive cells and esophageal squamous cell carcinoma （ESCC）.  The aim 
of this study was to clarify the prognostic value of FOXP3 expression in ESCC.  
Ninety-ve patients who were diagnosed with primary ESCC and underwent sub-
total esophagectomy during 2009 and 2010 were retrospectively analyzed.  Deepest 
sections from each tumor were selected for immunohistochemistry and the number 
of FOXP3 positive cells was counted.  The median number was used as a cutoff 
to divide into FOXP3 positive and FOXP3 negative subgroups.  Relationships 
between FOXP3 expression and clinicopathological features, disease-free survival 
（DFS） and overall survival （OS） were determined.  Statistical values of p ＜
0.05 were considered signicant.  FOXP3 positive cells were found in all 95 cases 
and the number of FOXP3 positive cells was significantly higher in the peri-
tumor compartment than in the intra-tumor compartment （p＝ 0.0006）.  For this 
reason, the peri-tumor compartment numbers were used for all of the association 
studies.  Results showed that the FOXP3 positive group had a signicantly larger 
mean tumor size （43.8 ± 4.1 mm vs 29.1 ± 4.0 mm, p ＝ 0.0055）, and the FOXP3 
negative group had a signicantly higher percentage of deep invasion （T2, T3, T4） 
（p＝ 0.0399）.  There was no signicant association for DFS, however, for OS the 
FOXP3 positive group demonstrated a signicantly better prognosis （p＝ 0.0024）.  
Multivariate analysis showed that peri-tumor FOXP3 expression is an independent 
prognostic factor for OS （p＝ 0.0035）.  Peri-tumoral FOXP3 expression is an inde-
pendent and favorable prognostic factor for ESCC.
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Introduction
　Tumor-infiltrating lymphocytes （TILs） may play an important role in the host immune 
response to cancer in the tumor microenvironment.  Many studies have shown a clear associa-
tion between TILs and patient survival in several types of human cancers.  Regulatory T cells, in 
particular, have been reported to inhibit the antitumor response in mice 1，2） and the depletion of 
regulatory T cells can result in an effective antitumor response 3，4）.  Additional studies report that 
the regulatory T cell population is increased in peripheral blood and tumor tissues in patients 
with different types of human cancer 5-8）.
　In 2003, the transcription factor forkhead box protein 3 （FOXP3） was reported to be a mas-
ter control gene for thymically derived naturally occurring regulatory T cells 9）.  Since then, many 
studies have shown an association between a high density of tumor-inltrating FOXP3 positive 
cells and poor prognosis in various human cancers.  These include ovarian 7）, pancreatic 10）, lung 11）, 
and hepatocellular carcinomas 12）.  In contrast, other studies have found that a high density 
of tumor-inltrating FOXP3 positive cells may be associated with improved patient survival in 
colorectal cancer 13）.
　There have been few reports describing the relationship between tumor-inltrating FOXP3 pos-
itive cells and esophageal squamous cell carcinoma （ESCC） and the issue remains controversial. 
Yoshioka et al suggested that the number of tumor-inltrating FOXP3 positive regulatory T cells 
is not a predictive factor for patient survival in ESCC 14）, whereas Xue et al reported that the 
expression of FOXP3 in ESCC closely correlates to lymphatic invasion and pathological stage. 
They concluded that FOXP3 expression might play an important role in cancer progression15）. 
The aim of this study was to clarify the prognostic value of FOXP3 expression in ESCC.
Methods
Patients and specimens
　A series of 100 consecutive unselected patients who were diagnosed with primary ESCC and 
underwent video-assisted thoracic subtotal esophagectomy during 2009 and 2010 at the Depart-
ment of Surgery, Division of General and Gastroenterological Surgery, Showa University School 
of Medicine, were retrospectively analyzed.  Five cases that underwent subtotal esophagectomy 
after endoscopic submucosal dissection （ESD） were excluded from the current study.  All of the 
surgically obtained tumor tissues were stained using hematoxylin-eosin and the histopathologic 
classication and grade were determined according to the Japanese Classication of Esophageal 
Cancer （10th edition, April 2008, The Japan Esophageal Society）.  The clinicopathological data 
for each patient was recorded and filed at the Department of Pathology, Showa University 
School of Medicine.
Follow-Up
　The most recent collection of data to determine disease-free survival （DFS） and overall sur-
vival （OS） was performed on July 31, 2012.  DFS was dened as the interval between the date 
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of surgery and recurrence or most recent follow-up.  OS was dened as the interval between the 
date of surgery and death.  The diagnosis of recurrence was based on an elevated serum SCC 
and typical imaging appearance.  Patients with conrmed recurrence received further treatment, 
such as surgery, radiotherapy, chemotherapy （CT） or chemoradiotherapy （CRT）.
Immunohistochemistry
　For immunohistochemistry analysis, one of the deepest sections from each tumor was selected 
for evaluation.  Formalin-xed and parafn-embedded specimens were deparafnised and dehy-
drated.  Monoclonal FOXP3 antibody （clone 236A/E7 ; Abcam, Cambridge, UK ; dilution 1 : 100） 
was used.  Staining was performed using a fully automated Ventana Benchmark XT slide stainer 
（Ventana Medical Systems, Inc., Tucson, Arizona, USA）.
Evaluation of FOXP3 positive cells
　The number of FOXP3 positive cells was counted in each specimen using an optical micro-
scope （Olympus Optical Co. Ltd., Tokyo, Japan）.  Two scorers were blinded to the clinical 
information and the mean number of FOXP3 positive cells was determined for each slide.  Cells 
were counted in two different compartments in each tumor : within the intra-tumor compartment, 
defined as tumor cell nests ; and within the peri-tumor compartment, defined as the stromal 
region surrounding the tumor cell nests within a distance of 5 mm.  In each compartment, 
FOXP3 positive cells were counted at a magnication of 400 ×.  The median number of FOXP3 
positive cells in each compartment was used as a cutoff to divide into FOXP3 positive group 
and FOXP3 negative subgroups.
Statistical analysis
　Statistical analysis using the Student’s t test or the Mann-Whitney U test was performed 
where appropriate.  The Kaplan-Meier method was used to estimate OS and DFS, and differ-
ences were compared using the log-rank test.  Multivariate analysis of prognostic factors was 
performed using the Cox proportional hazard model.  Values of p＜ 0.05 were considered statisti-
cally signicant.
Results
Characteristics
　Patient characteristics are shown in Table 1.  The study population consisted of 80 males and 
15 females, and the mean age was 64.6 years （range 41 to 90 years）.  There were 60 cases that 
received CT using either 5-uorouracil and Nedaplatin alone, or CRT before the operation.  Fif-
teen patients had not received any induction therapy.
Immunohistochemistry staining
　Examples of immunohistochemistry staining are shown in Fig. 1.  We found FOXP3 positive 
cells in all cases.  As a control, we also examined a distant compartment.  This was dened as a 
Yusuke WADA, et al136
normal epithelial stromal compartment sufciently distant from the tumor nests.  Both intra- and 
peri-tumor compartments expressed signicantly higher numbers of FOXP3 positive cells than 
the distant compartments （p＜ 0.0001） （Table 2）, and the number of FOXP3 positive cells in 
the peri-tumor compartment was signicantly higher than in the intra-tumor compartment （p＝
0.0002）.
Table 1.  Patient characteristics and
　　　　　　　    clinicopathological parameters
Characteristics n＝ 95
Age
Mean value ± SD 64.6 ± 0.9
Range 4.1-9.0
Gender
Male 80
Female 15
Tumor size （mm）
Mean value ± SD 36.5 ± 2.9
Range 0-165
Tumor differentiation
Well 25
Moderately 55
Poorly 15
Induction therapy
Present 60
Absent 35
Lymphatic invasion
Present 43
Absent 52
Vascular invasion
Present 49
Absent 46
T classification
T0 6
T1a 9
T1b 33
T2 10
T3 32
T4  5
N classification
N0 48
N1 11
N2 27
N3 8
N4 1
Pathological stage
0 15
Ⅰ 20
Ⅱ 21
Ⅲ 34
Ⅳ  5
SD, standard deviation
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Relationship between FOXP3 expression and patient characteristics
　The relationships between FOXP3 expression and the clinicopathological characteristics of the 
patients are shown in Table 3.  In the peri-tumor compartment, the FOXP3 positive group had 
a signicantly larger mean tumor size （43.8 ± 4.1 mm） than the FOXP3 negative group （p ＝
0.0055）, whereas there was no signicant association between tumor size and FOXP3 subgroup 
in the intra-tumor compartment.  Also, in the peri-tumor compartment, the FOXP3 negative 
group had a high percentage of deep invasive tumors （T2, T3, T4） compared to the FOXP3 
Fig. 1.  Representative immunohistochemical staining 
A） Tumor nests （intra-tumor compartment） and surrounding 
stroma （peri-tumor compartment） （40 × magnification）.
B） FOXP3 positive cells in the intra-tumor compartment 
（400 × magnification）.
C） FOXP3 positive cells in the peri-tumor compartment 
（400 × magnification）.
Table 2.  The number of FOXP3 positive cells counted in each compartment.
             P-value is estimated by the Wilcoxon matched-pairs signed-rank test.
Compartment Range Mean ± SD Median p-value
Intra-tumor 1-233 63.6 ± 5.1 50
0.0002
＜ 0.0001Peri-tumor 5-413 88.9 ± 7.6 70
Distant stroma 0-161 27.4 ± 2.5 20
SD ; standard deviation
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positive group （p ＝ 0.0399）.  Other clinicopathological parameters such as patient’s age, sex, 
tumor differentiation, lymphatic and vascular invasion, lymph node metastasis and pathological 
stage showed no significant differences between subgroups in both the intra- and peri-tumor 
compartments.
Disease-free survival and overall survival analysis
　Fig. 2 shows DFS for both FOXP3 expression subgroups.  There were no signicant differences 
in DFS in either compartment.  In contrast, Fig. 3 shows that in OS, the FOXP3 positive group 
had a signicantly better prognosis compared to the FOXP3 negative group （p＝ 0.0024）.
Multivariate analysis
　Table 4 shows the multivariate analysis which indicates that only peri-tumor FOXP3 expression 
is an independent prognostic factor for OS （p＝ 0.0035）.  Other factors, such as age, gender, 
Table 3.  Relationship between clinicopathological features and FOXP3 expression in intra- and 
peri-tumor compartments
Characteristics
Intra-tumor FOXP3 Peri-tumor FOXP3
Negative
（n＝ 48）
Positive
（n＝ 47） p-value
Negative
（n＝ 49）
Positive
（n＝ 46） p-value
Age 64.8 ± 1.4 64.5 ± 1.4 0.7459 65.8 ± 1.3 64.2 ± 1.4 0.6955
Gender
Male 40 40 0.8126 43 37 0.3273
Female  8  7  6  9
Tumor size （mm） 34.6±4.0 38.5±4.3 0.551 29.7±4.0 43.8±4.1 ＜ 0.01
Tumor differentiation
Well 16  9 0.1314 12 13 0.4355
Moderately 23 32 27 28
Poorly  9  6 10  5
Induction therapy
Present 32 28 0.4735 34 26 0.1934
Absent 16 19 15 20
Lymphatic invasion
Present 24 19 0.3482 21 22 0.6267
Absent 24 28 28 24
Vascular invasion
Present 27 22 0.3569 24 25 0.6007
Absent 21 25 25 21
T classification
T0, T1a, T1b 23 25 0.6071 20 28 ＜ 0.05
T2, T3, T4 25 22 29 18
N classification
N0 29 19 0.0506 25 23 0.9208
N1, N2, N3, N4 19 28 24 23
Stage
0, Ⅰ, Ⅱ 29 27 0.7686 27 29 0.4312
Ⅲ, Ⅳ 19 20 22 17
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tumor size, depth of invasion, lymphatic and vascular invasion, lymph node metastasis, pathologi-
cal stage, presence or absence of induction therapy, and intra-tumor FOXP3 expression had no 
signicant association with prognosis.
Discussion
　There are many studies evaluating FOXP3 expression by immunohistochemistry in different 
tissue compartments.  Sahar et al evaluated FOXP3 expression in intra-tumor, peri-tumor and dis-
tant stromal compartments in human breast cancer, and reported that FOXP3 positive cells were 
seen more often in distant stromal compartments 16）.  Another study evaluated FOXP3 expression 
in intra-tumor and peri-tumor regions in hepatocellular carcinoma and reported that the number 
of FOXP3 positive T cells in the intra-tumor region was signicantly higher than that in the 
peri-tumor region 17）.  In contrast, our study showed a signicantly higher number of FOXP posi-
Fig. 2.  Disease-free survival （DFS） rates for intra- and peri-tumoral FOXP3 expression were estimated by 
the Kaplan-Meier method. The log-rank test was applied to compare between groups.
Fig. 3.  Overall survival （OS） rates for intra- and peri-tumoral FOXP3 expression were estimated by the 
Kaplan-Meier method. The log-rank test was applied to compare between groups.
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tive cells in the peri-tumor compartment.  This difference may result from differences in methods 
and evaluation strategies.  Previously, only one study has evaluated FOXP3 expression in fresh 
esophageal squamous cell carcinoma tissue 15）, however that study did not discriminate between 
compartments.  Our study is the rst study to evaluate FOXP3 expression in different tumor 
microenvironments in ESCC and found higher numbers of FOXP3 positive cells in the peri-
tumor compartment.
　Previous studies indicate that FOXP3 expression is significantly decreased after chemo-
therapy18）.  Our study includes 60 patients who underwent either CT or CRT induction therapy. 
Our study also showed signicantly lower FOXP3 positive expression in the induction therapy 
group, supporting the previous study.  Our additional analysis indicates that prognosis for the 
FOXP3 positive group was signicantly better than for the FOXP3 negative group regardless of 
the absence or presence of induction therapy （Fig. 4）.  However, the mechanism of how induc-
Table 4.  Multivariate analyses and clinicopathological features
Variables Hazard ratio 95% Cl p-value
Age （≧ 65 vs ＜ 65） （years） 0.333 0.088-1.047 0.0603
Gender （male vs female） 0.884 0.195-6.198 0.8835
Tumor size （≧ 30 mm vs ＜ 30 mm） 1.424 0.453-4.586 0.5438
Induction therapy （present vs absent） 1.050 0.215-5.729 0.9514
Lymphatic invasion （present vs absent） 1.057 0.243-5.000 0.9416
Vascular invasion （present vs absent） 0.938 0.292-3.101 0.9141
Depth of invasion （T0/T1a/T1b vs T2/T3/T4） 0.702 0.083-13.237 0.7735
Lymph node metastasis （present vs absent） 0.632 0.070-5.715 0.6903
Pathological stage （0/Ⅰ/Ⅱ vs Ⅲ/Ⅳ） 0.297 0.010-4.740 0.4115
Intra-tumor FOXP3 （negative vs positive） 0.790 0.244-2.542 0.6889
Peri-tumor FOXP3 （negative vs positive） 7.991 1.877-56.516 0.0035
Cl, confdence interval.
Fig. 4.  The FOXP3 positive group had a significantly better prognosis regardless of the absence or presence 
of induction therapy.
141FOXP3 expression in esophageal cancer
tion therapy affects the expression of FOXP3 is still unclear and further study is necessary.
　We also analyzed how differences in induction therapy, such as CT or CRT, affected FOXP3 
expression.  There were 36 cases of CT, 21 cases of CRT and 3 cases in which the therapy 
regimen was unknown.  Comparing CT and CRT, the CT group had a significantly higher 
percentage of FOXP3 positive cases and CRT had significantly higher percentage of FOXP3 
negative cases in both the intra-tumor （p＝ 0.0008） and peri-tumor （p＝ 0.0003） compartments. 
However, the differences between CT or CRT did not affect DFS （p＝ 0.3570） or OS （p＝
0.1322）.  This result may indicate that CRT has a greater regulatory effect on FOXP3 expression 
than CT, but still further study is necessary.
　With respect to the relationships between FOXP3 expression and clinicopathological character-
istics, our study showed signicance in tumor size and the depth of invasion （Table 3）.  In the 
peri-tumor compartment, the FOXP3 negative group had a high percentage of deep invasive （T2, 
T3, T4） tumors and poorer prognosis in OS, but contrary to our expectations, it had a smaller 
mean tumor size.  We speculate that the reason for this discrepancy is that we did not exclude 
some cases of so-called supercial spread-type ESCC in this study, and this is reected in the 
tumor size.
　The log-rank test revealed that ESCC patients with high numbers of FOXP3 positive T cells 
in the peri-tumor compartment had a better prognosis.  A previous study showed a similar 
result, but multivariate analysis showed no signicance 14）.  In contrast, our multivariate analysis 
indicates that the density of peri-tumoral FOXP3 positive T cells may be an independent 
prognostic factor for OS in ESCC.  Our literature search indicates that this is the only study 
to report FOXP3 expression as an improved and independent prognostic factor for esophageal 
squamous cell carcinoma.
　Although further study is necessary, FOXP3 expression can be used as an independent prog-
nostic factor for ESCC ; high numbers of FOXP3 positive T cells in the peri-tumor compartment 
predict a better prognosis.
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